# Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4

> **NCT04382339** · PHASE1,PHASE2 · COMPLETED · sponsor: **Beni-Suef University** · enrollment: 99 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** SOF/RBV/PegINFα-2

## Key facts

- **NCT ID:** NCT04382339
- **Lead sponsor:** Beni-Suef University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2020-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04382339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04382339, "Sofosbuvir/Pegylated-interferon Plus Ribavirin With HCV Genotype 4". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT04382339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*